Plain-English translation of NCT07063693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new tool called —a fluorescent dye—to help surgeons see brain tumors more clearly during surgery. The dye is injected before your operation and glows under special imaging equipment, making it easier for your surgeon to identify and remove tumor tissue. Researchers want to find the right dose of this medication that works best without causing safety problems.
High-grade brain tumors are difficult to remove completely because it's hard for surgeons to see exactly where the tumor ends and healthy brain tissue begins. This medication could help surgeons see the tumor boundaries more clearly, which might lead to better surgery outcomes and fewer complications.
You likely qualify if…
You likely don't qualify if…
Before your scheduled brain surgery, you will receive an injection of the fluorescent dye. Your medical team will then collect several blood samples over about an hour, along with a urine sample and heart monitoring (EKG). During your surgery, surgeons will use a special imaging system to see how much dye is in your tumor and surrounding tissue. After surgery, while you're in the hospital recovering, you'll have repeat blood, urine, and heart monitoring tests.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Dartmouth College, National Cancer Institute (NCI)
Enrollment target
~33 participants
Started
February 2026
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Keith D Paulsen, PhD
Dartmouth-Hitchcock Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.